Lexicon Pharmaceuticals Inc LXRX.OQ LXRX.O is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
The The Woodlands Texas-based company is expected to report a 1,708.3% increase in revenue to $2.93 million from $162 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Lexicon Pharmaceuticals Inc is for a loss of 16 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $5.00, above its last closing price of $1.27.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.19 | -0.19 | -0.17 | Beat | 9.9 |
Mar. 31 2024 | -0.20 | -0.20 | -0.20 | Met | -1.3 |
Dec. 31 2023 | -0.22 | -0.22 | -0.20 | Beat | 7.9 |
Sep. 30 2023 | -0.21 | -0.21 | -0.21 | Met | 2.2 |
Jun. 30 2023 | -0.17 | -0.17 | -0.22 | Missed | -25.9 |
Mar. 31 2023 | -0.18 | -0.18 | -0.17 | Beat | 5.2 |
Dec. 31 2022 | -0.14 | -0.13 | -0.16 | Missed | -19.4 |
Sep. 30 2022 | -0.14 | -0.14 | -0.13 | Beat | 6.7 |
This summary was machine generated November 9 at 00:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments